Search Results

PROMIS SF v1.0-Dyspnea-Severity 5b Patient Reported Outcomes Measurement Information System - Short Form - Dyspnea-Severity 5b For patients with dyspnea LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The PROMIS SF v1.0 – Dyspnea-Severity 5b includes 5 items from part I of the FACIT-Dyspnea adopted by the PROMIS Health Organization. MEASURE NAME: Patient Reported Outcomes Measurement Information System - Short Form - Dyspnea-Severity 5b VERSION: 1 NUMBER OF ITEMS: 5 PATIENT POPULATION: Dyspnea patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 4 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Severity TIME FOR COMPLETION: Less than 5 minutes SCORING: PROMIS Scoring Service: http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions RELATED MEASURES: FACIT-Dyspnea , PROMIS SF v1.0 – Dyspnea-Severity 10a , PROMIS SF v1.0 – Dyspnea-Severity 5a DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PROMIS-SF-v1.0-Dyspnea-Severity 5b can be obtained by registering for permission. Users are not permitted to translate the PROMIS-SF-v1.0-Dyspnea-Severity 5b without permission from FACIT.org. Permission from FACIT.org to translate the PROMIS-SF-v1.0-Dyspnea-Severity 5b may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Choi, S., Victorson, D., Yount, S., Anton, S., & Cella, D. Development of a conceptual framework and calibrated item banks to measure patient reported dyspnea severity and related functional limitations. Value in Health 2011; 14: 291-306. Ruo, B., Choi, S., Baker, D., Grady, K., & Cella,D. Development and validation of a computer adaptive test measuring dyspnea in heart failure. Journal of Cardiac Failure 2010; 16(8): 659-668. doi: 10.1016/j.cardfail.2010.03.002. Victorson, D., Anton, S., Hamilton, A., Yount, S., & Cella, D. A conceptual model of the experience of dyspnea and functional limitations in COPD. Value in Health 2009; 12(6): 1018-1025. Yount, S., Choi, S., Victorson, D., Ruo, B., Ray, D., Cella, D., Anton, S., & Hamilton, A. (2011) Brief, valid measures of dyspnea and related functional limitations in chronic obstructive pulmonary disease (COPD). Value in Health 2011; 14: 307-315. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Dyspnea Functional Assessment of Chronic Illness Therapy - Dyspnea-10 item LEARN MORE PROMIS SF v1.0 – Dyspnea Severity 10a Patient-Reported Outcomes Measurement Information System Short Form - Dyspnea Severity 10a LEARN MORE PROMIS SF v1.0 – Dyspnea Severity 5a Patient-Reported Outcomes Measurement Information System Short Form - Dyspnea Severity 5a LEARN MORE

BACK FACIT-F Scoring Downloads Download DOC

BACK CCSQ English Downloads Download PDF - Baseline Download DOC - Baseline Download PDF - On Therapy Download DOC - On Therapy

BACK PROMIS SF v1.0-Dyspnea-Severity 5a Scoring Downloads http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions

BACK PROMIS SF v1.0 Fatigue 10a Scoring Downloads http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions

FACT-EGFRI-18 Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item Version For patients treated with EGFR Inhibitors LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-EGFRI-18 measure: MEASURE NAME: Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item Version (FACT-EGFRI-18) VERSION: 4 NUMBER OF ITEMS: 18 PATIENT POPULATION: Cancer patients 18 years and older undergoing EGFR treatment RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: None TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. RELATED MEASURES: FACT-Taxane , FACT/GOG-NTX , FACIT-AI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-EGFRI-18 can be obtained by registering for permission. Users are not permitted to translate the FACT-EGFRI-18 without permission from FACIT.org. Permission from FACIT.org to translate the FACT-EGFRI-18 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Boers-Doets, C., Gelderblom, H., Lacouture, M. Bredle, J., Epstein, J., Schrama, N., Gall, H., Ouwerkerk, J., Brakenhoff, J., Nortier, J.,& Kaptein, A. Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. European Journal of Oncology Nursing 2013; 17(6): 802-807. doi: 10.1016/j.ejon.2013.03.004. Wagner, L., Berg, S., Gandhi, M., Hlubocky, F., Webster, K., Aneja, M., Cella, D., & Lacouture, M. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Journal of Supportive Care in Cancer 2014; 21(4): 1033-1041. Doi: 10.1007/s00520-012-1623-4. Wong SF, Unger JM, Wade JL 3rd, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, Velasco MR Jr, Floyd JD, Esparaz BT, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moinpour CM. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. J Patient Rep Outcomes. 2020 Jul 8;4(1):54. doi: 10.1186/s41687-020-00220-x. PMID: 32642992; PMCID: PMC7343679. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Taxane Functional Assessment of Cancer Therapy – Taxane LEARN MORE FACT/GOG-NTX Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity LEARN MORE FACIT-AI Functional Assessment of Chronic Illness Therapy - Ascites Index LEARN MORE

FACT-Br-CI Functional Assessment of Cancer Therapy – Brain Cognitive Index For patients with Brain cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT-Br-CI measures self-reported cognition in patients with brain cancer. Studies that included the FACT-Br could be retrospectively analyzed to assess subjective cognitive outcomes, enriching the information from prior research. Integration of the FACT-Br-CI in routine clinical care may be an efficient method of monitoring cognition. MEASURE NAME: Functional Assessment of Cancer Therapy – Brain Cognitive Index (FACT-Br-CI) VERSION: 4 NUMBER OF ITEMS: 9 PATIENT POPULATION: Brain cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Cognitive Index TIME FOR COMPLETION: 5 minutes SCORING: Manual scoring template, some items are reverse scored. RELATED MEASURES: FBrSI , NFBrSI-24 , FACT-Br DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Br-CI can be obtained by registering for permission. Users are not permitted to translate the FACT-Br-CI without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Br-CI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Zarrella GV, Perez A, Dietrich J, Parsons MW. Reliability and validity of a novel cognitive self-assessment tool for patients with cancer. Neurooncol Pract . 2021 Jul 21;8(6):691-698. doi: 10.1093/nop/npab045. PMID: 34777838; PMCID: PMC8579089. Weitzner, M.A., Meyers, C.A., Gelke, C., Byrne, K., Cella, D.F., & Levin, V.A. The Functional Assessment of Cancer Therapy (FACT) Scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995; 75(5): 1151-1161. Thavarajah, N., Bedard, G., Zhang, L., Cella, D., Beaumont, J., Tsao, M., Barnes, E., Danjoux, C., Sahgal, A., Soliman, H., & Chow, E. The Functional Assessment of Cancer Therapy – Brain (FACT-Br) for assessing quality of life in patients with brain metastases: A comparison of recall periods. Journal of Pain Management 2013; 6(3): 223-234. Thavarajah, N., G., Zhang, L., Cella, D., Beaumont, J. Tsao, M., Barnes, E., Danjoux, C., Sahgal, A., Soliman, H., & Chow, E. Psychometric validation of the functional assessment of cancer therapy—brain (FACT-Br) for assessing quality of life in patients with brain metastases Supportive Care in Cancer 2014; 22 (4): 1017-1028. doi: 10.1007/s00520-013-2060-8. Verhaak, E., Schimmel, W. C., Sitskoorn, M. M., Bakker, M., Hanssens, P. E., & Gehring, K. (2019). Multidimensional assessment of fatigue in patients with brain metastases before and after Gamma Knife radiosurgery. Journal of neuro-oncology , 144 (2), 377-384. Verhaak, E., Gehring, K., Hanssens, P. E., & Sitskoorn, M. M. (2019). Health-related quality of life of patients with brain metastases selected for stereotactic radiosurgery. Journal of neuro-oncology , 143 (3), 537-546. Verhaak, E., Schimmel, W. C., Gehring, K., Emons, W. H., Hanssens, P. E., & Sitskoorn, M. M. (2020). Health-related quality of life after Gamma Knife radiosurgery in patients with 1–10 brain metastases. Journal of Cancer Research and Clinical Oncology , 1-11. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FBrSI Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 15 Item Version LEARN MORE NRBrSI-24 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 24 Item Version LEARN MORE FACT-Br Functional Assessment of Cancer Therapy – Brain LEARN MORE

FACIT-SWiP Functional Assessment of Chronic Illness Therapy - Satisfaction with Pharmacist Satisfaction with Pharmacist Scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACIT-SWiP measure: MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Satisfaction with Pharmacist (FACIT-SWiP) VERSION: 4 NUMBER OF ITEMS: 7 PATIENT POPULATION: Patients 18 and older receiving pharmacy care RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Satisfaction with Pharmacist Subscale TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-TS-G , FACIT-TS-PS , CCSQ DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-SWiP can be obtained by registering for permission. Users are not permitted to translate the FACIT-SWiP without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-SWiP may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Hernandez, L., Chang, C.H., Cella, D., Corona, M., Shiomoto, G., & McGuire, D.B. Development and validation of the Satisfaction with Pharmacist Scale. Pharmacotherapy 2000; 20(7): 837-843. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-TS-G Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction – General LEARN MORE FACIT-TS-PS Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - Patient Satisfaction LEARN MORE CCSQ Chemotherapy Convenience and Satisfaction Questionnaire LEARN MORE

FACIT-Sp Non-Illness Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being - Non-Illness Version Non-Illness Version of the 12-item Spiritual Well-Being Scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACIT-Sp Non-Illness Version is identical to the FACIT-Sp-12 aside from minor modifications to two items in which “illness” has been revised to “difficult times.” MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being (FACIT-Sp) Non-Illness Version VERSION: 4 NUMBER OF ITEMS: 12 PATIENT POPULATION: Subjects 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Spiritual Well-Being, Meaning, Peace, Faith TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-Sp , FACIT-Sp-Ex , FACIT-SP-12 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-Sp Non-Illness Version can be obtained by registering for permission. Users are not permitted to translate the FACIT-Sp Non-Illness Version without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-Sp Non-Illness may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bormann, J., Aschbacher, K., Wetherell, J., Roesch, S., & Redwine., L. Effects of faith/assurance on cortisol levels are enhanced by a spiritual mantram intervention in adults with HIV: A randomized trial. Journal of Psychosomatic Research 2009; 66: 161–171. doi: 10.1016/j.jpsychores.2008.09.017. Bormann, J., Gifford, A., Shively, M., Smith, T., Redwine, L., Kelly, A., Becker, S., Gershwin, M., Bone, P., & Belding, W. Effects of Spiritual Mantram Repetition on HIV Outcomes: A Randomized Controlled Trial. Journal of Behavioral Medicine 2006; 29(4): 359-376. doi: 10.1007/s10865-006-9063-6. Brady, M.J., Peterman, A.H., Fitchett, G., Mo, M., & Cella, D. A case for including spirituality in quality of life measurement in oncology. Psycho-Oncology 1999; 8: 417-428. Bredle, J., Salsman, J., Debb, S., Arnold, B., & Cella, D. Spiritual Well-Being as a component of health-related quality of life: the functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp). Religions 2011; 2(1): 77-94. doi: 10.3390/rel2010077. Canada, A, Murphy, P., Fitchett, G., Peterman, A., & Schover, L. A 3-factor model for the FACIT-Sp. Psycho-Oncology 2008; 17: 908–916. doi: 10.1002/pon.1307. Cotton, S., Levine, E., Fitzpatrick, C., Dold, K, & Targ, E. Exploring the relationships among spiritual well-being, quality of life, and psychological adjustment in women with breast cancer. Psycho-Oncology 1999; 8: 429–438. Dapueto, J., Servente, L., Francolino, C., & Hahn, E. Determinants of Quality of Life in Patients with Cancer: A South American Study. Cancer 2005; 103(5): 1072-1081. doi: 10.1002/cncr.20870. Edmondson, D., Park, C., Blank, T., Fenster, J., & Mills, M. Deconstructing spiritual well-being: existential well-being and HRQOL in cancer survivors. Psycho-Oncology 2008; 17: 161–169. doi: 10.1002/pon.1197. Fradelos, E., Tzavella, F., Koukia, E., Tsaras, K., Papathanasiou, I., Aroni, A., Alikari, V., Ralli, M., Bredle, J., & Zyga1, S. The translation, validation and cultural adaptation of functional assessment of chronic illness therapy – spiritual well-being 12 (FACIT-SP12) scale in Greek language. Mater Sociomed 2016; 28(3): 229-234. doi: 10.5455/msm.2016.28.229-234. Jarafi, N., Zamani, A., Lazenby, M., Farajzadegan, Z., Emami, H., & Loghmani, A. Translation and validation of the Persian version of the functional assessment of chronic illness therapy—Spiritual well-being scale (FACIT-Sp) among Muslim Iranians in treatment for cancer. Palliative and Supportive Care 2013; 11: 29–35. doi:10.1017/S1478951512000727. Krupski, T., Kwan, L., Fink, A., Sonn, G., Maliski, S., & Litwin, M. Spirituality Influences Health Related Quality of Life in Men with Prostate Cancer. Psycho-Oncology 2006; 15: 121–131. doi: 10.1002/pon.929. Lazenby, M., Khatib, J., 2, Al-Khair, F., & Neamat, M. Psychometric properties of the Functional Assessment of Chronic Illness Therapy—Spiritual Well-being (FACIT-Sp) in an Arabic-speaking, predominantly Muslim population. Psycho-Oncology 2011; 22(1): 220-227. doi: 10.1002/pon.2062. McClain, C., Rosenfeld, B., & Breitbart, W. Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. The Lancet 2003; 361: 1603-1607. McClain-Jacobson, C., Rosenfeld, B., Rosenfeld, B., Kosinski, A., Pessin, H., Cimino, J., & Breitbart, W. Belief in an afterlife, spiritual well-being and end-of-life despair in patients with advanced cancer. General Hospital Psychiatry 2004; 26: 484-486. doi: 10.1016/j.genhosppsych. Morgan, P., Gaston-Johansson, F., & Mock, V. Spiritual Well-Being, Religious Coping, and the Quality of Life of African American Breast Cancer Treatment: A Pilot Study. The ABNF Journal 2006; 73-77. Murphy, P., Canada, A., Fitchett, G., Stein, K., Portier, K., Crammer, C., & Peterman, A. An examination of the 3-factor model and structural invariance across racial/ethnic groups for the FACIT-Sp: a report from the American Cancer Society’s Study of Cancer Survivors-II (SCS-II). Psycho-Oncology 2010; 19: 264–272. doi: 10.1002/pon.1559. Perkins, E., Small, B., Balducci, L., Extermann, M., Robb, C., & Haley, W. Individual differences in well-being in older breast cancer survivors. Critical Reviews in Oncology/Hematology 2007; 62: 74-83. doi: 10.1016/j.critrevonc.2006.11.002. Peterman, A., Fitchett, G., Brady, M., & Hernandez, L. Measuring Spiritual Well-Being in People With Cancer: The Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being Scale (FACIT-Sp). Annals of Behavioral Medicine 2002; 24(1):49–58. Rodin, G., Zimmermann, C., Rydall, A., Jones, J., Shepherd, A., Moore, M., Fruh, M., Donner, A., Gagliese, L. The Desire for Hastened Death in Patients with Metastatic Cancer. Journal of Pain and Symptom Management 2007; 33(6): 661-674. doi: 10.1016/j.jpainsymman. Rodin, G., Lo, C., Mikulincer, M., Donner, A., Gagliese, L., & Zimmermann, C. Pathways to distress: The multiple determinants of depression, hopelessness, and the desire for hasted death in metastatic cancer patients. Social Science & Medicine 2008; 68: 562–569. doi: 10.1016/j.socscimed. Schnoll, R., Harlow, L., & Brower, L. Spirituality, Demographic, and Disease Factors, and Adjustment to Cancer. Cancer Practice 2000; 8(6): 298-304. Stefanek, M., McDonald, P., & Hess, S. Religion, Spirituality and Cancer: Current Status and Methodological Challenges. Psycho-Oncology 2005; 14: 450–463. doi: 10.1002/pon.861. Stojković, S. & Prlić, N. Effect of faith on the acceptance of chronic disease patients. South Eastern Europe Health Sciences Journal 2012; 2(1): 52-61. Tate, D. & Forchheimer, M. Quality of Life, Life Satisfaction, and Spirituality: Comparing Outcomes Between Rehabilitation and Cancer Patients. American Journal of Physical Medicine & Rehabilitation 2002; 81(6): 400-410. Trevino, K., Pargament, K., Cotton, S., Leonard. A., Hahn, J., Caprini-Faigin, C., & Tsevat, J. Religious Coping and Physiological, Psychological, Social, and Spiritual Outcomes in Patients with HIV/AIDS: Cross-sectional and Longitudinal Findings. AIDS and Behavior 2010; 14: 379-389. doi: 10.1007/s10461-007-9332-6. Visser, A., Garssen, B., & Vingerhoets, A. Spirituality and well-being in cancer patients: a review. Psycho-Oncology 2010; 19: 565–572. doi: 10.1002/pon. Zavala, M., Maliski, S., Kwan, L., Fink, A., & Litwin, M. Spirituality and quality of life in low-income men with metastatic prostate cancer. Psycho-Oncology 2009; 18: 753–761. doi: 10.1002/pon.1460. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Sp Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being LEARN MORE FACIT-Sp-Ex Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being Expanded Version LEARN MORE FACIT-Sp-12 Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale LEARN MORE

BACK FACIT-D English Downloads Download PDF Download DOC

BACK FHNSI Scoring Downloads Download DOC

FACIT-COST COST: A FACIT Measure of Financial Toxicity For financial toxicity LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Developed in conjunction with the University of Chicago, the COST is a patient-reported outcome measure that describes the financial distress experienced by cancer patients. Since its initial publication, an additional item from the FACIT System has been included to screen for financial toxicity and to provide a good global summary item for financial toxicity. MEASURE NAME: COST: A FACIT Measure of Financial Toxicity (FACIT-COST) VERSION: 2 NUMBER OF ITEMS: 12 PATIENT POPULATION: Cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Financial Toxicity TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. RELATED MEASURES: FACT-G , FACT-G7 , FACT-GP DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the COST can be obtained by registering for permission. Users are not permitted to translate the COST without permission from FACIT.org. Permission from FACIT.org to translate the COST may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References de Souza J.A., Yap B.J., Wroblewski K., Blinder V., Araújo F.S., Hlubocky F.J., Nicholas L.H., O'Connor J.M., Brockstein B., Ratain M.J., Daugherty C.K., Cella D. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer 2017 Feb 1;123(3):476-484. doi: 10.1002/cncr.30369. Epub 2016 Oct 7. PMID: 27716900; PMCID: PMC5298039. Sadigh, G., Switchenko, J., Weaver, K.E. et al. Correlates of financial toxicity in adult cancer patients and their informal caregivers. Support Care Cancer (2021). https://doi.org/10.1007/s00520-021-06424-1. Ezeife D.A., Morganstein B.J., Lau S., Law J.H., Le L.W., Bredle J., Cella D., Doherty M.K., Bradbury P., Liu G., Sacher A., Shepherd F.A., Leighl N.B. Financial Burden Among Patients with Lung Cancer in a Publically Funded Health Care System. Clin Lung Cancer 2019 Jul;20(4):231-236. doi: 10.1016/j.cllc.2018.12.010. Epub 2018 Dec 22. PMID: 30797721. Huntington S.F., Weiss B.M., Vogl D.T., Cohen A.D., Garfall A.L., Mangan P.A., Doshi J.A., Stadtmauer E.A. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol 2015 Oct;2(10):e408-16. doi: 10.1016/S2352-3026(15)00151-9. Epub 2015 Sep 17. PMID: 26686042. Patel MR, Zhang G, Heisler M, Song PXK, Piette JD, Shi X, Choe HM, Smith A, Resnicow K. Measurement and validation of the Comprehensive Score for financial toxicity (COST) in a population with diabetes. Diabetes Care, 2022 (In Press). Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-G Functional Assessment of Cancer Therapy - General LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy - General - 7 Item Version LEARN MORE FACT-GP Functional Assessment of Cancer Therapy - General Population LEARN MORE